Global Glioblastoma Multiforme Treatment Market By Type of Treatment (Surgery, Radiotherapy , Chemotherapy, Tumor Treating Fields (TTF) Therapy, Targeted Drug Therapy, Supportive (Palliative) Care, Others);By Mode of Action (Immunological, Metabolic, Pharmacological); By Demographic (Kids, Adults); By End Users (Hospitals and Clinics, Research Institutes, Pharmaceutical Companies, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Diseases have plagued humans since time immemorial, and the medical sciences sector is constantly trying to eradicate various diseases, or trying to find a cure for the same. One such disease that has drastically affected human beings, and is associated with is immense complications is brain tumor. Brain tumor results from a growth of abnormal cell division in the brain, resulting in unwarranted growth. Brain tumor can either be non-cancerous or cancerous. The growth of brain tumors is highly specific, and the growth rate, along with the location of the growth determines its effect on the human nervous system. Brain tumors that originate in the brain are referred to as primary brain tumors, whereas the tumor can reach the brain from different parts of the body through the spread of cancerous cells. The resulting brain tumor is called as secondary (metastatic) brain tumors. The most feared and common type of cancerous brain tumor is glioblastoma multiforme (GBM), and the prognosis for the same is extremely complicated. The treatment methods which are currently in existence has a low success rate, and scientists are increasingly trying to raise the survival rate through the inception of advanced treatment methods. GBM accounts for around 60% of the deaths related to brain tumors. The tumor presents unique challenges due to various factors such as the localization of the tumor in the brain, high resistance to conventional therapy methods, tumor-stimulated seizures, transfer of malignant cells into adjacent tissues, and limited self-healing ability of the brain, amongst others. The tumor can be detected using sophisticated medical imaging techniques. Diagnostic imaging technology such as computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI) are being used by highly trained medical professionals for identifying the location of the tumor for accurate treatment. Magnetic resonance spectroscopy (MRS), on the other hand, is used to study the chemical profile of the tumor, while intraoperative MRI is being used during surgical process for tumor removal. The rise in the number of GBM cases around the globe, coupled with growth in investment to increase the accuracy of treatment methods, is leading to the growth of the global glioblastoma multiforme treatment market.
In terms of revenue, global glioblastoma multiforme treatment market is expected to grow at a CAGR of 12.67% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Glioblastoma Multiforme Treatment Market Revenue & Forecast, (US$ Million), 2015 – 2029
Type of Treatment Outlook:
Though the treatment of glioblastoma multiforme is complex in nature, and is associated with limited success, there are multiple treatment types available in the global glioblastoma multiforme treatment market. They include surgery, radiotherapy, chemotherapy, tumor treating fields (TTF) therapy, targeted drug therapy, amongst others. The most common treatment method is the surgical removal of tumor cells, which is followed by radiotherapy and chemotherapy. In surgery, the main objective is the removal of a large chunk of tumor cells without damaging the neighbouring brain tissue which are pivotal for the normal functioning of the nervous system. The complete removal of the GBM is considered impossible, as tumor is surrounded by a section of migrating cells that invade the surrounding brain tissues. Surgery is mainly used for the debulking of the growth, and it has the potential to extend the lives of some patients, and provide a higher quality of remaining life.
Region Outlook:
As far as the regions in the global glioblastoma multiforme treatment market are concerned, North America was the prominent region in terms of revenue in 2020. The advancement in medical care technology in the U.S. and Canada, coupled with the presence of medical conglomerates such as Pfizer, Roche and Merck, amongst others is a major reason for the higher share of North America in the global glioblastoma multiforme treatment market. Amgen, for instance, provides an antiangiogenic that blocks signalling of angiopoietin-Tie2, and limits the growth endothelial cells associated with the tumor. The healthcare infrastructure in the U.S. and Canada is considered to be amongst the best in the world. A significant number of individuals also migrate to the U.S. for availing brain tumor treatment due to the presence of top-notch professionals that are skilled when it comes to surgical tumor removal, or other forms of therapy. Future advancements in medicine is expected to bring down the cost of treatment in the U.S., and this will lead to the growth in revenue in the North American glioblastoma multiforme treatment market, as the diagnosis and therapy will be accessible and affordable to a wider range of individuals.
Competitive Landscape
The report provides both, qualitative and quantitative research of global glioblastoma multiforme treatment market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of key players operating in the global glioblastoma multiforme treatment market are Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., DelMar Pharmaceuticals, NOXXON Pharma, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), amongst others.
Global Glioblastoma Multiforme Treatment Market
By Type of Treatment
- Surgery
- Radiotherapy
- Chemotherapy
- Tumor treating fields (TTF) therapy
- Targeted drug therapy
- Supportive (palliative) care
- Others
By Mode of Action
- Immunological
- Metabolic
- Pharmacological
By Demographic
- Kids
- Adults
By End Users
- Hospitals and Clinics
- Research Institutes
- Pharmaceutical Companies
- Others
By Region
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Glioblastoma Multiforme Treatment Market
6.
Market
Synopsis: Glioblastoma Multiforme
Treatment Market
7.
Glioblastoma
Multiforme Treatment Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Glioblastoma Multiforme Treatment
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Glioblastoma Multiforme Treatment Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Glioblastoma Multiforme
Treatment Market
8.
Global
Glioblastoma Multiforme Treatment Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn)
8.2. Global Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
8.2.1. Surgery
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market Forecast,
2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Radiotherapy
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Chemotherapy
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.3.3.
Market
Forecast, 2021 - 2029
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.2.4. Tumor treating fields (TTF) therapy
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.4.3.
Market
Forecast, 2021 - 2029
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2020
8.2.4.5.1.2. Market Forecast, 2021 - 2029
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2020
8.2.4.5.2.2. Market Forecast, 2021 - 2029
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2020
8.2.4.5.3.2. Market Forecast, 2021 - 2029
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2020
8.2.4.5.4.2. Market Forecast, 2021 - 2029
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2020
8.2.4.5.5.2. Market Forecast, 2021 - 2029
8.2.5. Targeted drug therapy
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.5.3.
Market
Forecast, 2021 - 2029
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2020
8.2.5.5.1.2. Market Forecast, 2021 - 2029
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2020
8.2.5.5.2.2. Market Forecast, 2021 - 2029
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2020
8.2.5.5.3.2. Market Forecast, 2021 - 2029
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2020
8.2.5.5.4.2. Market Forecast, 2021 - 2029
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2020
8.2.5.5.5.2. Market Forecast, 2021 - 2029
8.2.6. Supportive (palliative) care
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.6.3.
Market
Forecast, 2021 - 2029
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2020
8.2.6.5.1.2. Market Forecast, 2021 - 2029
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2020
8.2.6.5.2.2. Market Forecast, 2021 - 2029
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2020
8.2.6.5.3.2. Market Forecast, 2021 - 2029
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2020
8.2.6.5.4.2. Market Forecast, 2021 - 2029
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2020
8.2.6.5.5.2. Market Forecast, 2021 - 2029
8.2.7. Others
8.2.7.1.
Definition
8.2.7.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.7.3.
Market
Forecast, 2021 - 2029
8.2.7.4.
Compound
Annual Growth Rate (CAGR)
8.2.7.5.
Regional
Bifurcation
8.2.7.5.1.
North
America
8.2.7.5.1.1. Market Estimation, 2015 - 2020
8.2.7.5.1.2. Market Forecast, 2021 - 2029
8.2.7.5.2.
Europe
8.2.7.5.2.1. Market Estimation, 2015 - 2020
8.2.7.5.2.2. Market Forecast, 2021 - 2029
8.2.7.5.3.
Asia
Pacific
8.2.7.5.3.1. Market Estimation, 2015 - 2020
8.2.7.5.3.2. Market Forecast, 2021 - 2029
8.2.7.5.4.
Middle
East and Africa
8.2.7.5.4.1. Market Estimation, 2015 - 2020
8.2.7.5.4.2. Market Forecast, 2021 - 2029
8.2.7.5.5.
Latin
America
8.2.7.5.5.1. Market Estimation, 2015 - 2020
8.2.7.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Type of Treatment
9.
Global
Glioblastoma Multiforme Treatment Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
9.2.1. Immunological
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2. Metabolic
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3. Pharmacological
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.3.3.
Market
Forecast, 2021 - 2029
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Mode of Action
10. Global Glioblastoma Multiforme Treatment
Market Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
10.2.1. Kids
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Adults
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Demographic
11. Global Glioblastoma Multiforme Treatment
Market Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1. Hospitals and Clinics
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 -
2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 - 2020
11.2.1.5.1.2. Market Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2020
11.2.1.5.2.2. Market Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2020
11.2.1.5.3.2. Market Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2020
11.2.1.5.4.2. Market Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 - 2020
11.2.1.5.5.2. Market Forecast, 2021 - 2029
11.2.2. Research Institutes
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 -
2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 - 2020
11.2.2.5.1.2. Market Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2020
11.2.2.5.2.2. Market Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2020
11.2.2.5.3.2. Market Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2020
11.2.2.5.4.2. Market Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 - 2020
11.2.2.5.5.2. Market Forecast, 2021 - 2029
11.2.3. Pharmaceutical Companies
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 -
2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market Estimation, 2015 - 2020
11.2.3.5.1.2. Market Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2020
11.2.3.5.2.2. Market Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2020
11.2.3.5.3.2. Market Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2020
11.2.3.5.4.2. Market Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market Estimation, 2015 - 2020
11.2.3.5.5.2. Market Forecast, 2021 - 2029
11.2.4. Others
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 -
2020
11.2.4.3. Market Forecast, 2021 - 2029
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market Estimation, 2015 - 2020
11.2.4.5.1.2. Market Forecast, 2021 - 2029
11.2.4.5.2. Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2020
11.2.4.5.2.2. Market Forecast, 2021 - 2029
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2020
11.2.4.5.3.2. Market Forecast, 2021 - 2029
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2020
11.2.4.5.4.2. Market Forecast, 2021 - 2029
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market Estimation, 2015 - 2020
11.2.4.5.5.2. Market Forecast, 2021 - 2029
11.3. Key Segment for Channeling Investments
11.3.1. By End Users
12. North America Glioblastoma Multiforme
Treatment Market Analysis and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn)
12.2. North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
12.2.1. Surgery
12.2.2. Radiotherapy
12.2.3. Chemotherapy
12.2.4. Tumor treating fields (TTF) therapy
12.2.5. Targeted drug therapy
12.2.6. Supportive (palliative) care
12.2.7. Others
12.3. North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
12.3.1. Immunological
12.3.2. Metabolic
12.3.3. Pharmacological
12.4. North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
12.4.1. Kids
12.4.2. Adults
12.5. North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.1. Hospitals and Clinics
12.5.2. Research Institutes
12.5.3. Pharmaceutical Companies
12.5.4. Others
12.6. North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Glioblastoma Multiforme Treatment Market
Revenue (US$ Mn) and Forecasts, By Type of Treatment
12.6.1.1.1. Surgery
12.6.1.1.2. Radiotherapy
12.6.1.1.3. Chemotherapy
12.6.1.1.4. Tumor treating fields (TTF) therapy
12.6.1.1.5. Targeted drug therapy
12.6.1.1.6. Supportive (palliative) care
12.6.1.1.7. Others
12.6.1.2. U.S Glioblastoma Multiforme Treatment Market
Revenue (US$ Mn) and Forecasts, By Mode of Action
12.6.1.2.1. Immunological
12.6.1.2.2. Metabolic
12.6.1.2.3. Pharmacological
12.6.1.3. U.S Glioblastoma Multiforme Treatment Market
Revenue (US$ Mn) and Forecasts, By Demographic
12.6.1.3.1. Kids
12.6.1.3.2. Adults
12.6.1.4. U.S Glioblastoma Multiforme Treatment Market
Revenue (US$ Mn) and Forecasts, By End Users
12.6.1.4.1. Hospitals and Clinics
12.6.1.4.2. Research Institutes
12.6.1.4.3. Pharmaceutical Companies
12.6.1.4.4. Others
12.6.2. Canada
12.6.2.1. Canada Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
12.6.2.1.1. Surgery
12.6.2.1.2. Radiotherapy
12.6.2.1.3. Chemotherapy
12.6.2.1.4. Tumor treating fields (TTF) therapy
12.6.2.1.5. Targeted drug therapy
12.6.2.1.6. Supportive (palliative) care
12.6.2.1.7. Others
12.6.2.2. Canada Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
12.6.2.2.1. Immunological
12.6.2.2.2. Metabolic
12.6.2.2.3. Pharmacological
12.6.2.3. Canada Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
12.6.2.3.1. Kids
12.6.2.3.2. Adults
12.6.2.4. Canada Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.2.4.1. Hospitals and Clinics
12.6.2.4.2. Research Institutes
12.6.2.4.3. Pharmaceutical Companies
12.6.2.4.4. Others
12.6.3. Mexico
12.6.3.1. Mexico Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
12.6.3.1.1. Surgery
12.6.3.1.2. Radiotherapy
12.6.3.1.3. Chemotherapy
12.6.3.1.4. Tumor treating fields (TTF) therapy
12.6.3.1.5. Targeted drug therapy
12.6.3.1.6. Supportive (palliative) care
12.6.3.1.7. Others
12.6.3.2. Mexico Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
12.6.3.2.1. Immunological
12.6.3.2.2. Metabolic
12.6.3.2.3. Pharmacological
12.6.3.3. Mexico Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
12.6.3.3.1. Kids
12.6.3.3.2. Adults
12.6.3.4. Mexico Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.3.4.1. Hospitals and Clinics
12.6.3.4.2. Research Institutes
12.6.3.4.3. Pharmaceutical Companies
12.6.3.4.4. Others
12.6.4. Rest of North America
12.6.4.1. Rest of North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
12.6.4.1.1. Surgery
12.6.4.1.2. Radiotherapy
12.6.4.1.3. Chemotherapy
12.6.4.1.4. Tumor treating fields (TTF) therapy
12.6.4.1.5. Targeted drug therapy
12.6.4.1.6. Supportive (palliative) care
12.6.4.1.7. Others
12.6.4.2. Rest of North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
12.6.4.2.1. Immunological
12.6.4.2.2. Metabolic
12.6.4.2.3. Pharmacological
12.6.4.3. Rest of North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
12.6.4.3.1. Kids
12.6.4.3.2. Adults
12.6.4.4. Rest of North America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1. Hospitals and Clinics
12.6.4.4.2. Research Institutes
12.6.4.4.3. Pharmaceutical Companies
12.6.4.4.4. Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Type of Treatment
12.7.3. By Mode of Action
12.7.4. By Demographic
12.7.5. By End Users
13. Europe Glioblastoma Multiforme Treatment
Market Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Europe Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn)
13.2. Europe Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
13.2.1. Surgery
13.2.2. Radiotherapy
13.2.3. Chemotherapy
13.2.4. Tumor treating fields (TTF) therapy
13.2.5. Targeted drug therapy
13.2.6. Supportive (palliative) care
13.2.7. Others
13.3. Europe Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
13.3.1. Immunological
13.3.2. Metabolic
13.3.3. Pharmacological
13.4. Europe Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
13.4.1. Kids
13.4.2. Adults
13.5. Europe Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1. Hospitals and Clinics
13.5.2. Research Institutes
13.5.3. Pharmaceutical Companies
13.5.4. Others
13.6. Europe Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
13.6.1.1.1. Surgery
13.6.1.1.2. Radiotherapy
13.6.1.1.3. Chemotherapy
13.6.1.1.4. Tumor treating fields (TTF) therapy
13.6.1.1.5. Targeted drug therapy
13.6.1.1.6. Supportive (palliative) care
13.6.1.1.7. Others
13.6.1.2. France Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
13.6.1.2.1. Immunological
13.6.1.2.2. Metabolic
13.6.1.2.3. Pharmacological
13.6.1.3. France Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
13.6.1.3.1. Kids
13.6.1.3.2. Adults
13.6.1.4. France Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.4.1. Hospitals and Clinics
13.6.1.4.2. Research Institutes
13.6.1.4.3. Pharmaceutical Companies
13.6.1.4.4. Others
13.6.2. The UK
13.6.2.1. The UK Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
13.6.2.1.1. Surgery
13.6.2.1.2. Radiotherapy
13.6.2.1.3. Chemotherapy
13.6.2.1.4. Tumor treating fields (TTF) therapy
13.6.2.1.5. Targeted drug therapy
13.6.2.1.6. Supportive (palliative) care
13.6.2.1.7. Others
13.6.2.2. The UK Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
13.6.2.2.1. Immunological
13.6.2.2.2. Metabolic
13.6.2.2.3. Pharmacological
13.6.2.3. The UK Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
13.6.2.3.1. Kids
13.6.2.3.2. Adults
13.6.2.4. The UK Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.2.4.1. Hospitals and Clinics
13.6.2.4.2. Research Institutes
13.6.2.4.3. Pharmaceutical Companies
13.6.2.4.4. Others
13.6.3. Spain
13.6.3.1. Spain Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
13.6.3.1.1. Surgery
13.6.3.1.2. Radiotherapy
13.6.3.1.3. Chemotherapy
13.6.3.1.4. Tumor treating fields (TTF) therapy
13.6.3.1.5. Targeted drug therapy
13.6.3.1.6. Supportive (palliative) care
13.6.3.1.7. Others
13.6.3.2. Spain Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
13.6.3.2.1. Immunological
13.6.3.2.2. Metabolic
13.6.3.2.3. Pharmacological
13.6.3.3. Spain Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
13.6.3.3.1. Kids
13.6.3.3.2. Adults
13.6.3.4. Spain Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.3.4.1. Hospitals and Clinics
13.6.3.4.2. Research Institutes
13.6.3.4.3. Pharmaceutical Companies
13.6.3.4.4. Others
13.6.4. Germany
13.6.4.1. Germany Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
13.6.4.1.1. Surgery
13.6.4.1.2. Radiotherapy
13.6.4.1.3. Chemotherapy
13.6.4.1.4. Tumor treating fields (TTF) therapy
13.6.4.1.5. Targeted drug therapy
13.6.4.1.6. Supportive (palliative) care
13.6.4.1.7. Others
13.6.4.2. Germany Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
13.6.4.2.1. Immunological
13.6.4.2.2. Metabolic
13.6.4.2.3. Pharmacological
13.6.4.3. Germany Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
13.6.4.3.1. Kids
13.6.4.3.2. Adults
13.6.4.4. Germany Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.4.4.1. Hospitals and Clinics
13.6.4.4.2. Research Institutes
13.6.4.4.3. Pharmaceutical Companies
13.6.4.4.4. Others
13.6.5. Italy
13.6.5.1. Italy Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
13.6.5.1.1. Surgery
13.6.5.1.2. Radiotherapy
13.6.5.1.3. Chemotherapy
13.6.5.1.4. Tumor treating fields (TTF) therapy
13.6.5.1.5. Targeted drug therapy
13.6.5.1.6. Supportive (palliative) care
13.6.5.1.7. Others
13.6.5.2. Italy Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
13.6.5.2.1. Immunological
13.6.5.2.2. Metabolic
13.6.5.2.3. Pharmacological
13.6.5.3. Italy Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
13.6.5.3.1. Kids
13.6.5.3.2. Adults
13.6.5.4. Italy Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.5.4.1. Hospitals and Clinics
13.6.5.4.2. Research Institutes
13.6.5.4.3. Pharmaceutical Companies
13.6.5.4.4. Others
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
13.6.6.1.1. Surgery
13.6.6.1.2. Radiotherapy
13.6.6.1.3. Chemotherapy
13.6.6.1.4. Tumor treating fields (TTF) therapy
13.6.6.1.5. Targeted drug therapy
13.6.6.1.6. Supportive (palliative) care
13.6.6.1.7. Others
13.6.6.2. Nordic Countries Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
13.6.6.2.1. Immunological
13.6.6.2.2. Metabolic
13.6.6.2.3. Pharmacological
13.6.6.3. Nordic Countries Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
13.6.6.3.1. Kids
13.6.6.3.2. Adults
13.6.6.4. Nordic Countries Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1. Hospitals and Clinics
13.6.6.4.2. Research Institutes
13.6.6.4.3. Pharmaceutical Companies
13.6.6.4.4. Others
13.6.6.5. Nordic Countries Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
13.6.7.1.1. Surgery
13.6.7.1.2. Radiotherapy
13.6.7.1.3. Chemotherapy
13.6.7.1.4. Tumor treating fields (TTF) therapy
13.6.7.1.5. Targeted drug therapy
13.6.7.1.6. Supportive (palliative) care
13.6.7.1.7. Others
13.6.7.2. Benelux Union Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
13.6.7.2.1. Immunological
13.6.7.2.2. Metabolic
13.6.7.2.3. Pharmacological
13.6.7.3. Benelux Union Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
13.6.7.3.1. Kids
13.6.7.3.2. Adults
13.6.7.4. Benelux Union Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.7.4.1. Hospitals and Clinics
13.6.7.4.2. Research Institutes
13.6.7.4.3. Pharmaceutical Companies
13.6.7.4.4. Others
13.6.7.5. Benelux Union Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
13.6.8.1.1. Surgery
13.6.8.1.2. Radiotherapy
13.6.8.1.3. Chemotherapy
13.6.8.1.4. Tumor treating fields (TTF) therapy
13.6.8.1.5. Targeted drug therapy
13.6.8.1.6. Supportive (palliative) care
13.6.8.1.7. Others
13.6.8.2. Rest of Europe Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
13.6.8.2.1. Immunological
13.6.8.2.2. Metabolic
13.6.8.2.3. Pharmacological
13.6.8.3. Rest of Europe Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
13.6.8.3.1. Kids
13.6.8.3.2. Adults
13.6.8.4. Rest of Europe Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.4.1. Hospitals and Clinics
13.6.8.4.2. Research Institutes
13.6.8.4.3. Pharmaceutical Companies
13.6.8.4.4. Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Type of Treatment
13.7.3. By Mode of Action
13.7.4. By Demographic
13.7.5. By End Users
14. Asia Pacific Glioblastoma Multiforme
Treatment Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn)
14.2. Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
14.2.1. Surgery
14.2.2. Radiotherapy
14.2.3. Chemotherapy
14.2.4. Tumor treating fields (TTF) therapy
14.2.5. Targeted drug therapy
14.2.6. Supportive (palliative) care
14.2.7. Others
14.3. Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
14.3.1. Immunological
14.3.2. Metabolic
14.3.3. Pharmacological
14.4. Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
14.4.1. Kids
14.4.2. Adults
14.5. Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1. Hospitals and Clinics
14.5.2. Research Institutes
14.5.3. Pharmaceutical Companies
14.5.4. Others
14.6. Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
14.6.1.1.1. Surgery
14.6.1.1.2. Radiotherapy
14.6.1.1.3. Chemotherapy
14.6.1.1.4. Tumor treating fields (TTF) therapy
14.6.1.1.5. Targeted drug therapy
14.6.1.1.6. Supportive (palliative) care
14.6.1.1.7. Others
14.6.1.2. China Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
14.6.1.2.1. Immunological
14.6.1.2.2. Metabolic
14.6.1.2.3. Pharmacological
14.6.1.3. China Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
14.6.1.3.1. Kids
14.6.1.3.2. Adults
14.6.1.4. China Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.1.4.1. Hospitals and Clinics
14.6.1.4.2. Research Institutes
14.6.1.4.3. Pharmaceutical Companies
14.6.1.4.4. Others
14.6.2. Japan
14.6.2.1. Japan Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
14.6.2.1.1. Surgery
14.6.2.1.2. Radiotherapy
14.6.2.1.3. Chemotherapy
14.6.2.1.4. Tumor treating fields (TTF) therapy
14.6.2.1.5. Targeted drug therapy
14.6.2.1.6. Supportive (palliative) care
14.6.2.1.7. Others
14.6.2.2. Japan Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
14.6.2.2.1. Immunological
14.6.2.2.2. Metabolic
14.6.2.2.3. Pharmacological
14.6.2.3. Japan Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
14.6.2.3.1. Kids
14.6.2.3.2. Adults
14.6.2.4. Japan Glioblastoma Multiforme Treatment Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.2.4.1. Hospitals and Clinics
14.6.2.4.2. Research Institutes
14.6.2.4.3. Pharmaceutical Companies
14.6.2.4.4. Others
14.6.3. India
14.6.3.1. India Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
14.6.3.1.1. Surgery
14.6.3.1.2. Radiotherapy
14.6.3.1.3. Chemotherapy
14.6.3.1.4. Tumor treating fields (TTF) therapy
14.6.3.1.5. Targeted drug therapy
14.6.3.1.6. Supportive (palliative) care
14.6.3.1.7. Others
14.6.3.2. India Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
14.6.3.2.1. Immunological
14.6.3.2.2. Metabolic
14.6.3.2.3. Pharmacological
14.6.3.3. India Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
14.6.3.3.1. Kids
14.6.3.3.2. Adults
14.6.3.4. India Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.3.4.1. Hospitals and Clinics
14.6.3.4.2. Research Institutes
14.6.3.4.3. Pharmaceutical Companies
14.6.3.4.4. Others
14.6.4. New Zealand
14.6.4.1. New Zealand Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
14.6.4.1.1. Surgery
14.6.4.1.2. Radiotherapy
14.6.4.1.3. Chemotherapy
14.6.4.1.4. Tumor treating fields (TTF) therapy
14.6.4.1.5. Targeted drug therapy
14.6.4.1.6. Supportive (palliative) care
14.6.4.1.7. Others
14.6.4.2. New Zealand Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
14.6.4.2.1. Immunological
14.6.4.2.2. Metabolic
14.6.4.2.3. Pharmacological
14.6.4.3. New Zealand Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
14.6.4.3.1. Kids
14.6.4.3.2. Adults
14.6.4.4. New Zealand Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.4.4.1. Hospitals and Clinics
14.6.4.4.2. Research Institutes
14.6.4.4.3. Pharmaceutical Companies
14.6.4.4.4. Others
14.6.5. Australia
14.6.5.1. Australia Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
14.6.5.1.1. Surgery
14.6.5.1.2. Radiotherapy
14.6.5.1.3. Chemotherapy
14.6.5.1.4. Tumor treating fields (TTF) therapy
14.6.5.1.5. Targeted drug therapy
14.6.5.1.6. Supportive (palliative) care
14.6.5.1.7. Others
14.6.5.2. Australia Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
14.6.5.2.1. Immunological
14.6.5.2.2. Metabolic
14.6.5.2.3. Pharmacological
14.6.5.3. Australia Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
14.6.5.3.1. Kids
14.6.5.3.2. Adults
14.6.5.4. Australia Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.5.4.1. Hospitals and Clinics
14.6.5.4.2. Research Institutes
14.6.5.4.3. Pharmaceutical Companies
14.6.5.4.4. Others
14.6.6. South Korea
14.6.6.1. South Korea Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
14.6.6.1.1. Surgery
14.6.6.1.2. Radiotherapy
14.6.6.1.3. Chemotherapy
14.6.6.1.4. Tumor treating fields (TTF) therapy
14.6.6.1.5. Targeted drug therapy
14.6.6.1.6. Supportive (palliative) care
14.6.6.1.7. Others
14.6.6.2. South Korea Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
14.6.6.2.1. Immunological
14.6.6.2.2. Metabolic
14.6.6.2.3. Pharmacological
14.6.6.3. South Korea Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
14.6.6.3.1. Kids
14.6.6.3.2. Adults
14.6.6.4. South Korea Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.6.4.1. Hospitals and Clinics
14.6.6.4.2. Research Institutes
14.6.6.4.3. Pharmaceutical Companies
14.6.6.4.4. Others
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
14.6.7.1.1. Surgery
14.6.7.1.2. Radiotherapy
14.6.7.1.3. Chemotherapy
14.6.7.1.4. Tumor treating fields (TTF) therapy
14.6.7.1.5. Targeted drug therapy
14.6.7.1.6. Supportive (palliative) care
14.6.7.1.7. Others
14.6.7.2. Southeast Asia Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
14.6.7.2.1. Immunological
14.6.7.2.2. Metabolic
14.6.7.2.3. Pharmacological
14.6.7.3. Southeast Asia Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
14.6.7.3.1. Kids
14.6.7.3.2. Adults
14.6.7.4. Southeast Asia Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.7.4.1. Hospitals and Clinics
14.6.7.4.2. Research Institutes
14.6.7.4.3. Pharmaceutical Companies
14.6.7.4.4. Others
14.6.7.5. Southeast Asia Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
14.6.8.1.1. Surgery
14.6.8.1.2. Radiotherapy
14.6.8.1.3. Chemotherapy
14.6.8.1.4. Tumor treating fields (TTF) therapy
14.6.8.1.5. Targeted drug therapy
14.6.8.1.6. Supportive (palliative) care
14.6.8.1.7. Others
14.6.8.2. Rest of Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
14.6.8.2.1. Immunological
14.6.8.2.2. Metabolic
14.6.8.2.3. Pharmacological
14.6.8.3. Rest of Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
14.6.8.3.1. Kids
14.6.8.3.2. Adults
14.6.8.4. Rest of Asia Pacific Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1. Hospitals and Clinics
14.6.8.4.2. Research Institutes
14.6.8.4.3. Pharmaceutical Companies
14.6.8.4.4. Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Type of Treatment
14.7.3. By Mode of Action
14.7.4. By Demographic
14.7.5. By End Users
15. Middle East and Africa Glioblastoma
Multiforme Treatment Market Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle East and Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn)
15.2. Middle East and Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn) and Forecasts, By Type of
Treatment
15.2.1. Surgery
15.2.2. Radiotherapy
15.2.3. Chemotherapy
15.2.4. Tumor treating fields (TTF) therapy
15.2.5. Targeted drug therapy
15.2.6. Supportive (palliative) care
15.2.7. Others
15.3. Middle East and Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
15.3.1. Immunological
15.3.2. Metabolic
15.3.3. Pharmacological
15.4. Middle East and Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
15.4.1. Kids
15.4.2. Adults
15.5. Middle East and Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.1. Hospitals and Clinics
15.5.2. Research Institutes
15.5.3. Pharmaceutical Companies
15.5.4. Others
15.6. Middle East and Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
15.6.1.1.1. Surgery
15.6.1.1.2. Radiotherapy
15.6.1.1.3. Chemotherapy
15.6.1.1.4. Tumor treating fields (TTF) therapy
15.6.1.1.5. Targeted drug therapy
15.6.1.1.6. Supportive (palliative) care
15.6.1.1.7. Others
15.6.1.2. Saudi Arabia Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
15.6.1.2.1. Immunological
15.6.1.2.2. Metabolic
15.6.1.2.3. Pharmacological
15.6.1.3. Saudi Arabia Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
15.6.1.3.1. Kids
15.6.1.3.2. Adults
15.6.1.4. Saudi Arabia Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.1.4.1. Hospitals and Clinics
15.6.1.4.2. Research Institutes
15.6.1.4.3. Pharmaceutical Companies
15.6.1.4.4. Others
15.6.2. UAE
15.6.2.1. UAE Glioblastoma Multiforme Treatment Market
Revenue (US$ Mn) and Forecasts, By Type of Treatment
15.6.2.1.1. Surgery
15.6.2.1.2. Radiotherapy
15.6.2.1.3. Chemotherapy
15.6.2.1.4. Tumor treating fields (TTF) therapy
15.6.2.1.5. Targeted drug therapy
15.6.2.1.6. Supportive (palliative) care
15.6.2.1.7. Others
15.6.2.2. UAE Glioblastoma Multiforme Treatment Market
Revenue (US$ Mn) and Forecasts, By Mode of Action
15.6.2.2.1. Immunological
15.6.2.2.2. Metabolic
15.6.2.2.3. Pharmacological
15.6.2.3. UAE Glioblastoma Multiforme Treatment Market
Revenue (US$ Mn) and Forecasts, By Demographic
15.6.2.3.1. Kids
15.6.2.3.2. Adults
15.6.2.4. UAE Glioblastoma Multiforme Treatment Market
Revenue (US$ Mn) and Forecasts, By End Users
15.6.2.4.1. Hospitals and Clinics
15.6.2.4.2. Research Institutes
15.6.2.4.3. Pharmaceutical Companies
15.6.2.4.4. Others
15.6.3. Egypt
15.6.3.1. Egypt Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
15.6.3.1.1. Surgery
15.6.3.1.2. Radiotherapy
15.6.3.1.3. Chemotherapy
15.6.3.1.4. Tumor treating fields (TTF) therapy
15.6.3.1.5. Targeted drug therapy
15.6.3.1.6. Supportive (palliative) care
15.6.3.1.7. Others
15.6.3.2. Egypt Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
15.6.3.2.1. Immunological
15.6.3.2.2. Metabolic
15.6.3.2.3. Pharmacological
15.6.3.3. Egypt Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
15.6.3.3.1. Kids
15.6.3.3.2. Adults
15.6.3.4. Egypt Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.3.4.1. Hospitals and Clinics
15.6.3.4.2. Research Institutes
15.6.3.4.3. Pharmaceutical Companies
15.6.3.4.4. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
15.6.4.1.1. Surgery
15.6.4.1.2. Radiotherapy
15.6.4.1.3. Chemotherapy
15.6.4.1.4. Tumor treating fields (TTF) therapy
15.6.4.1.5. Targeted drug therapy
15.6.4.1.6. Supportive (palliative) care
15.6.4.1.7. Others
15.6.4.2. Kuwait Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
15.6.4.2.1. Immunological
15.6.4.2.2. Metabolic
15.6.4.2.3. Pharmacological
15.6.4.3. Kuwait Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
15.6.4.3.1. Kids
15.6.4.3.2. Adults
15.6.4.4. Kuwait Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.4.4.1. Hospitals and Clinics
15.6.4.4.2. Research Institutes
15.6.4.4.3. Pharmaceutical Companies
15.6.4.4.4. Others
15.6.5. South Africa
15.6.5.1. South Africa Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
15.6.5.1.1. Surgery
15.6.5.1.2. Radiotherapy
15.6.5.1.3. Chemotherapy
15.6.5.1.4. Tumor treating fields (TTF) therapy
15.6.5.1.5. Targeted drug therapy
15.6.5.1.6. Supportive (palliative) care
15.6.5.1.7. Others
15.6.5.2. South Africa Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
15.6.5.2.1. Immunological
15.6.5.2.2. Metabolic
15.6.5.2.3. Pharmacological
15.6.5.3. South Africa Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
15.6.5.3.1. Kids
15.6.5.3.2. Adults
15.6.5.4. South Africa Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.5.4.1. Hospitals and Clinics
15.6.5.4.2. Research Institutes
15.6.5.4.3. Pharmaceutical Companies
15.6.5.4.4. Others
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn) and Forecasts, By Type of
Treatment
15.6.6.1.1. Surgery
15.6.6.1.2. Radiotherapy
15.6.6.1.3. Chemotherapy
15.6.6.1.4. Tumor treating fields (TTF) therapy
15.6.6.1.5. Targeted drug therapy
15.6.6.1.6. Supportive (palliative) care
15.6.6.1.7. Others
15.6.6.2. Rest of Middle East & Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
15.6.6.2.1. Immunological
15.6.6.2.2. Metabolic
15.6.6.2.3. Pharmacological
15.6.6.3. Rest of Middle East & Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
15.6.6.3.1. Kids
15.6.6.3.2. Adults
15.6.6.4. Rest of Middle East & Africa Glioblastoma
Multiforme Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1. Hospitals and Clinics
15.6.6.4.2. Research Institutes
15.6.6.4.3. Pharmaceutical Companies
15.6.6.4.4. Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Type of Treatment
15.7.3. By Mode of Action
15.7.4. By Demographic
15.7.5. By End Users
16. Latin America Glioblastoma Multiforme
Treatment Market Analysis and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn)
16.2. Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
16.2.1. Surgery
16.2.2. Radiotherapy
16.2.3. Chemotherapy
16.2.4. Tumor treating fields (TTF) therapy
16.2.5. Targeted drug therapy
16.2.6. Supportive (palliative) care
16.2.7. Others
16.3. Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
16.3.1. Immunological
16.3.2. Metabolic
16.3.3. Pharmacological
16.4. Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
16.4.1. Kids
16.4.2. Adults
16.5. Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
16.5.1. Hospitals and Clinics
16.5.2. Research Institutes
16.5.3. Pharmaceutical Companies
16.5.4. Others
16.6. Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
16.6.1.1.1. Surgery
16.6.1.1.2. Radiotherapy
16.6.1.1.3. Chemotherapy
16.6.1.1.4. Tumor treating fields (TTF) therapy
16.6.1.1.5. Targeted drug therapy
16.6.1.1.6. Supportive (palliative) care
16.6.1.1.7. Others
16.6.1.2. Brazil Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
16.6.1.2.1. Immunological
16.6.1.2.2. Metabolic
16.6.1.2.3. Pharmacological
16.6.1.3. Brazil Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
16.6.1.3.1. Kids
16.6.1.3.2. Adults
16.6.1.4. Brazil Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.4.1. Hospitals and Clinics
16.6.1.4.2. Research Institutes
16.6.1.4.3. Pharmaceutical Companies
16.6.1.4.4. Others
16.6.2. Argentina
16.6.2.1. Argentina Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
16.6.2.1.1. Surgery
16.6.2.1.2. Radiotherapy
16.6.2.1.3. Chemotherapy
16.6.2.1.4. Tumor treating fields (TTF) therapy
16.6.2.1.5. Targeted drug therapy
16.6.2.1.6. Supportive (palliative) care
16.6.2.1.7. Others
16.6.2.2. Argentina Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Mode of Action
16.6.2.2.1. Immunological
16.6.2.2.2. Metabolic
16.6.2.2.3. Pharmacological
16.6.2.3. Argentina Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By Demographic
16.6.2.3.1. Kids
16.6.2.3.2. Adults
16.6.2.4. Argentina Glioblastoma Multiforme Treatment
Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.2.4.1. Hospitals and Clinics
16.6.2.4.2. Research Institutes
16.6.2.4.3. Pharmaceutical Companies
16.6.2.4.4. Others
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Type of Treatment
16.6.3.1.1. Surgery
16.6.3.1.2. Radiotherapy
16.6.3.1.3. Chemotherapy
16.6.3.1.4. Tumor treating fields (TTF) therapy
16.6.3.1.5. Targeted drug therapy
16.6.3.1.6. Supportive (palliative) care
16.6.3.1.7. Others
16.6.3.2. Rest of Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Mode of Action
16.6.3.2.1. Immunological
16.6.3.2.2. Metabolic
16.6.3.2.3. Pharmacological
16.6.3.3. Rest of Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By Demographic
16.6.3.3.1. Kids
16.6.3.3.2. Adults
16.6.3.4. Rest of Latin America Glioblastoma Multiforme
Treatment Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.4.1. Hospitals and Clinics
16.6.3.4.2. Research Institutes
16.6.3.4.3. Pharmaceutical Companies
16.6.3.4.4. Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Type of Treatment
16.7.3. By Mode of Action
16.7.4. By Demographic
16.7.5. By End Users
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2020
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. Amgen, Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Amneal Pharmaceuticals
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Arbor Pharmaceuticals, LLC
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. DelMar Pharmaceuticals
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. F. Hoffmann-La Roche Ltd.
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Karyopharm Therapeutics, Inc.
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Merck & Co., Inc.
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. NOXXON Pharma
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Pfizer Inc.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Sumitomo Dainippon Pharma Oncology, Inc.
(Boston Biomedical, Inc.)
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Sun Pharmaceutical Industries Ltd.
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Teva Pharmaceutical Industries Ltd.
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.